Drug–drug interactions in patients with acute coronary syndrome across phases of treatment
- 27 November 2018
- journal article
- research article
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 14 (3) , 411-422
Abstract
The objective of this study is to evaluate potential drug–drug interactions (pDDIs) and risk factors for pDDIs in three phases of an acute coronary syndrome (ACS) treatment: from the point of first medical contact to the coronary angiography (first phase), after coronary angiography to the last day of hospitalization (second phase), and at discharge from hospital (third phase). This retrospective observational cohort clinical study was conducted at the Clinic for Cardiology of the Clinical Centre Kragujevac, a public tertiary care hospital in Kragujevac, Serbia. Micromedex® interaction checker was used to detect pDDIs. This study included 245 ACS patients. All patients were exposed to at least one pDDI in all the phases of treatment. Mean total number of pDDIs was 9.47 ± 6.07, 10.11 ± 6.92, and 6.29 ± 3.66 in first, second, and third phases, respectively. Age, > 6 h from the beginning of the symptoms to admission, primary PCI, STE-ACS, COPD, delirium, hyperlipidemia, hypertension, obesity, systolic blood pressure at admission, TIMI risk score at admission, ALT, LDL, number of physicians who prescribed drugs to a single patient, number of prescribed drugs, and various pharmacological classes increased risk of pDDIs. Mechanical ventilation, dementia, and drug allergy noted in the medical documentation protected against them. Effects of heart failure, diabetes, and aPTT depended on phase of treatment and severity of pDDI. In conclusion, physicians should be vigilant to the possibility of pDDIs in patients harbouring factors that may increase their rate.Keywords
Funding Information
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (175007)
This publication has 36 references indexed in Scilit:
- Ketorolac Use in Acute Coronary SyndromesThe American Journal of Medicine, 2013
- Drug–Drug Interactions in Cardiovascular Catheterizations and InterventionsJACC: Cardiovascular Interventions, 2012
- Prevalence of Antidepressant Prescription or Use in Patients with Acute Coronary Syndrome: A Systematic ReviewPLOS ONE, 2011
- Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactionsExpert Opinion on Drug Safety, 2011
- Drug-drug Interactions in Hospitalized Cardiac PatientsJournal of Young Pharmacists, 2011
- Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarctionCanadian Medical Association Journal, 2011
- Prevalence of drug–drug interactions at hospital entry and during hospital stay of patients in internal medicineEuropean Journal of Internal Medicine, 2008
- Increased Bleeding Risk With Concurrent Use of Selective Serotonin Reuptake Inhibitors and CoumarinsArchives of internal medicine (1960), 2008
- Drug interactions in the setting of acute coronary syndromes and dual anti-platelet therapyEuropean Heart Journal Supplements, 2006
- Specialist Care of Heart Failure Improves Appropriate Pharmacotherapy at the Expense of Greater Polypharmacy and Drug-InteractionsEuropean Journal of Heart Failure, 2004